RMD ResMed Inc.

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA.

More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay will be available approximately 24 hours after the live webcast ends and will be accessible for the following thirty (30) days.

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

For investors

+1 858.221.3304



For media

+1 619.510.1281

  





EN
18/12/2025

Underlying

RMDResMed Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

Free Trial
RMD RESMED INC.

ResMed Inc: 2 directors

A director at ResMed Inc sold 2,000 shares at 248.830USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

01/09/26 January 9, 2026 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 20...

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST /...

January 8, 2026 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthca...

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay...

December 18, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Receives FDA Clearance for Personalized Therapy Comfort Setting...

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy Technology uses real-world sleep data and machine learning to help people with sleep apnea start and stay on therapy  SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Setting...

December 8, 2025 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 202...

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026 Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) to...

October 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch